Stock grant lifts CVS (CVS) director Jeffrey Balser’s holdings to 15,717 shares

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Balser Jeffrey R. reported acquisition or exercise transactions in this Form 4 filing.

CVS Health Corp director Jeffrey R. Balser received a grant of 2,058 shares of common stock on May 14, 2026 at $97.15 per share. According to the footnote, the stock was issued as payment of a semi-annual retainer under the 2017 Incentive Compensation Plan. After this award, he directly owns 15,717 CVS shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Balser Jeffrey R.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,058	$97.15	$200K

Holdings After Transaction: Common Stock — 15,717 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares granted: 2,058 shares Grant price: $97.15 per share Shares held after grant: 15,717 shares

3 metrics

Shares granted 2,058 shares Common stock grant on May 14, 2026

Grant price $97.15 per share Market price used for semi-annual retainer

Shares held after grant 15,717 shares Director’s direct CVS holdings post-transaction

Key Terms

2017 Incentive Compensation Plan, semi-annual retainer, grant/award acquisition

3 terms

2017 Incentive Compensation Plan financial

"pursuant to the 2017 Incentive Compensation Plan."

semi-annual retainer financial

"issued in payment of a semi-annual retainer, at the market price"

grant/award acquisition financial

"transaction_action": "grant/award acquisition""

Form 4 Insider Transactions: What Each Field Means →

05/15/2026 - 05:19 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Balser Jeffrey R.

(Last)

(First)

(Middle)

ONE CVS DRIVE

(Street)

WOONSOCKET

RHODE ISLAND

02895

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CVS HEALTH Corp [ CVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/14/2026		A⁽¹⁾		2,058	A	$97.15	15,717	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the 2017 Incentive Compensation Plan.

	/s/ Jeffrey R. Balser	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did CVS (CVS) director Jeffrey R. Balser report in this Form 4?

Jeffrey R. Balser reported receiving 2,058 CVS common shares as a stock grant. The shares were issued at $97.15 each as part of his semi-annual retainer under the 2017 Incentive Compensation Plan, increasing his direct holdings to 15,717 shares.

Was the CVS (CVS) Form 4 transaction an open-market stock purchase?

No, the CVS Form 4 transaction was a compensation grant, not an open-market purchase. The 2,058 shares were issued as payment of a semi-annual director retainer at market price under the 2017 Incentive Compensation Plan, reflecting routine equity compensation.

How many CVS (CVS) shares does Jeffrey R. Balser hold after this grant?

After the reported grant, Jeffrey R. Balser directly holds 15,717 CVS common shares. This total includes the 2,058 shares issued on May 14, 2026 as a semi-annual retainer, granted at a market price of $97.15 per share under the company’s incentive plan.

What is the size and price of the CVS (CVS) director stock grant?

The director stock grant to Jeffrey R. Balser totaled 2,058 CVS common shares. The shares were valued at $97.15 each, matching the market price, and were issued as compensation for a semi-annual board retainer under the 2017 Incentive Compensation Plan.

How was the CVS (CVS) semi-annual retainer paid to Jeffrey R. Balser?

Jeffrey R. Balser’s semi-annual retainer was paid in CVS common stock rather than cash. He received 2,058 shares at a market-based price of $97.15 per share, issued pursuant to the company’s 2017 Incentive Compensation Plan as routine director compensation.